Neoadjuvant Chemotherapy and Radiation for Oesophageal Cancer
Author Information
Author(s): Lorenzen S, Brücher B, Zimmermann F, Geinitz H, Riera J, Schuster T, Roethling N, Höfler H, Ott K, Peschel C, Siewert J R, Molls M, Lordick F
Primary Institution: Technical University of Munich
Hypothesis
The optimal dosage and efficacy of oxaliplatin and 5-fluorouracil combined with concurrent radiotherapy as neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma are unknown.
Conclusion
Weekly oxaliplatin and continuous infusional 5-fluorouracil with concurrent radiotherapy provide promising histological response rates and high rates of tumour-free resection in locally advanced oesophageal squamous cell carcinoma.
Supporting Evidence
- Histopathological responses were observed in 10 of 16 patients (63%).
- Overall, 16 of the 25 patients (64%) who underwent resection had a histopathological response.
- Tumour-free resection (R0) was achieved in 80% of patients.
Takeaway
This study tested a new treatment for a type of throat cancer and found that it helped many patients have less cancer left after treatment and more successful surgeries.
Methodology
This was a multicentre, open-label, non-randomised phase I/II study assessing the maximum tolerated dose and histopathological response rate of the treatment.
Limitations
The study had a high postoperative mortality rate of 12% and a relatively low 2-year survival rate of 28%.
Participant Demographics
{"age_range":"19-67","median_age":60,"sex_distribution":{"male":25,"female":4}}
Statistical Information
P-Value
0.023
Confidence Interval
95% CI: 39–82%
Statistical Significance
p=0.023
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website